Freshfields advised AstraZeneca in its acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The acquisition will further expand the company’s rare disease pipeline.

The Freshfields team is led by corporate/M&A partner Sebastian L. Fain and senior associate Katie Stenstrom with support in Paris from partner Julien Rebibo together with counsel Arnaud Mouton. The team was supported by senior associate Anthony Paladino and associates Octavian David, Matt Del Gigante and Amelie Saurel and Côme Le Brun, partner Vinita Kailasanath and associates Jake Silvers and Madeleine Tavcar advised on life sciences matters; partners Brandon Gantus, Christel Cacioppo and Gwen Senlanne and associates Andrew Herman, Anne Reungoat, Clemence Bosse Pilon and Lina Zhu advised on executive compensation and benefits; partners Claude Stansbury and Vincent Daniel-Mayeur, together with counsel Thomas Metayer and associates Jessica Berman and Edouard Laperriere advised on tax matters; partners Justin Stewart-Teitelbaum and Jenny Leahy, counsel Laura Onken, senior associate Sam Fulliton and associates Remony Vials and Hattie Van Metre advised on competition matters; partner Jérôme Philippe and associate Jalil El Khanchoufi advised on foreign investment matters.

Learn more about this transaction here.